明略科技完成2亿美元E+轮融资 腾讯(00700.HK)加码
明略科技公布,完成2亿美元E+轮融资,由中俄投资基金(Russia-China Investment Fund)领投,旧有股东腾讯(00700.HK)及弘卓资本持续加码,东方明珠传媒产业基金、大湾区共同家园投资公司、中信证券投资、新加坡大华创投、Capthrone及China Sky Global跟投,E轮及E+轮共完成5亿美元融资。
公司表示,本轮融资後将以产品化战略为核心,在技术及市场方面加大投入,同时与投资人深入联动共同拓展「一带一路」战略下的国际化市场及新基建浪潮之下的产业数字化机会。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.